Effect of Cytoreductive Chemotherapy and a CCR5 Coreceptor Antagonist on HIV-1 Eradication

Inclusion Criteria: * Patients who give written consent to participate in the study * Age between 18 and 65 years old, included. * Chronic HIV-1 Demonstration of R5 viral tropism (use of CCR5 coreceptors) by genotyping in plasma samples stored * Patients that are to be treated with intensive chemotherapy for non Hodgkin lymphoma With or without stable antiretroviral therapy * Patients that are able to understand the purpose of the study and be available for scheduled appointments. * Both in the case of female and male patients, the patient agrees to use a double barrier method of contraception from the moment of signing the informed consent until 3 months after the end of their participation in the study. Exclusion Criteria: * To have planned antiretroviral treatment interruption during the participation in the study * Hypersensitivity to products used in this study * To be involved in another clinical trial or received an investigational drug within 3 months prior to the study initiation * To have contraindications or limitations to perform leukapheresis